The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors
This study investigated the effect of leptin (LEP) 2548A/G and leptin receptor (LEPR) Q223R polymorphisms on the levels of HDL, LDL, TG, and total cholesterol (t-chol). In addition, the interactions between examined polymorphisms, statin therapy and environmental factors on lipid profile were examined.
Adult diabetic patients (n-418) were recruited from diabetes/endocrine clinics in north of Jordan. Lipid profile was measured using standard protocols. Genotyping of LEP 2548A/G and LEPR Q223R polymorphisms was carried out using polymerase chain reaction-restriction fragment length polymorphisms.
No significant association between LEP 2548A/G and LEPR genotypes and levels of HDL (P = 0.83), LDL (P = 0.40), TG (P = 0.23) and t-chol (P = 0.91). However, in patient on atorvastatin, those with GG or GA genotypes of LEP 2548 experienced significantly higher levels of LDL compared with AA genotype of LEP 2548 (P < 0.002). Patients with dyslipidemia had higher TG in comparison with those without (P < 0.03). Smokers had lower HDL and higher TG levels compared with none smokers or previous smokers (P < 0.002 and P < 0.02, respectively). Female patients tend to have a higher HDL in comparison with male patients (P < 0.05). Patients with HbA1c value greater than or equal to 7 had higher LDL and t-chol compared with patients who had an HbA1c levels of <7 (P < 0.02 and < 0.005, respectively). Patients with disease duration of 5 or more years had a lower HDL compared with those patients with duration of <5 years (P < 0.03).
In conclusion, and although lipid profile regulation is a multifactorial process, -2548G/A LEP polymorphism seems to affect statins treatment response among diabetic patients. More studies are required to specifically define factors that influence lipid profiles interaction with statin treatment response especially among patients with diabetes.
KeywordsLeptin Leptin receptor Polymorphism Lipid profile Type II diabetes
- 7.Schmitz G, Schmitz-Madry A, Ugocsai P (2007) Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 18(2):164–173. doi:10.1097/MOL.0b013e328055508300041433-200704000-00008 PubMedCrossRefGoogle Scholar
- 10.Xu Y, Bao Q, He B, Pan Y, Zhang R, Mao X, Tang Z, Qu L, Zhu C, Tian F, Wang S (2012) Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin. J Endocrinol Invest 35(4):378–383. doi:10.3275/7797 PubMedGoogle Scholar
- 13.Boumaiza I, Omezzine A, Rejeb J, Rebhi L, Ouedrani A, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Bouslama A (2012) Relationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers. Genet Test Mol Biomarkers 16(7):726–733. doi:10.1089/gtmb.2011.0324 PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Nieters A, Becker N, Linseisen J (2002) Polymorphisms in candidate obesity genes and their interaction with dietary intake of n-6 polyunsaturated fatty acids affect obesity risk in a sub-sample of the EPIC-Heidelberg cohort. Eur J Nutr 41(5):210–221. doi:10.1007/s00394-002-0378-y PubMedCrossRefGoogle Scholar
- 24.Chagnon YC, Wilmore JH, Borecki IB, Gagnon J, Perusse L, Chagnon M, Collier GR, Leon AS, Skinner JS, Rao DC, Bouchard C (2000) Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab 85(1):29–34PubMedGoogle Scholar
- 28.Borggreve SE, De Vries R, Dullaart RP (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33(12):1051–1069 (pii: 1263)PubMedCrossRefGoogle Scholar
- 33.Hu D, Hannah J, Gray RS, Jablonski KA, Henderson JA, Robbins DC, Lee ET, Welty TK, Howard BV (2000) Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic American Indians: the strong heart study. Obes Res 8(6):411–421. doi:10.1038/oby.2000.51 PubMedCrossRefGoogle Scholar
- 38.Ginsberg HN, MacCallum PR (2009) The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 4(2):113–119. doi:10.1111/j.1559-4572.2008.00044.x PubMedCentralPubMedCrossRefGoogle Scholar
- 42.World Health Organization (2009) The tobacco epidemic. A global public health emergency. Tobacco or Health Programme on Substance Abuse, Tob. Alert Spec.WHO, Geneva, Switzerland, p 28Google Scholar
- 45.Neki NS (2002) Lipid profile in chronic smokers—a clinical study. JIACM 3(1):51–54Google Scholar